

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				<i>Complete If Known</i> Application Number 10/522,208 Filing Date October 27, 2005 First Named Inventor Mezher Ali et al. Art Unit 1625 Examiner Name Celia C. Chang	
Sheet	1	of	1	Attorney Docket No: AC-21-US	

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		SILVA, et al., Advances in Prodrug Design, Mini-Reviews in Medicinal Chemistry, 2005, Vol. 5, pp. 893-914.		
		WU, W. et al., Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug, J. Med. Chem., 2007, Vol. 50(15); pp. 3743-3746.		
		YILDIZ, Y. et al., Mutation of β -glucosidase 2 causes glycolipid storage disease and impaired male fertility, The Journal of Clinical Investigation, 2006, Vol. 116, No. 11, pp. 2985-2994.		

EXAMINER

DATE CONSIDERED